IL1B and colitis: In this study, we found that the HDAC6 inhibitor WT161 exerts a protective effect in a DSS-induced colitis murine model and blocks NLRP3 inflammasome activation, as IL-1β release and ASC oligomerization were inhibited in the WT161-treated group.